跳至主要内容

MedPath Trial Home

机构资讯 AI 研究

数据来源：ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

搜索试验。追踪管线。洞察审批。由 AI 驱动的临床研究情报平台。

产品

临床试验
药物情报
全球审批
深度研究
价格方案

资源

常见问题
搜索

公司

资讯
关于我们
联系我们

法律

隐私政策
服务条款

免责声明： 本网站提供信息检索和数据分析服务。内容不构成医疗建议。适应性评估仅供参考，不能替代合格医疗专业人员的咨询。数据来源于公共注册库和监管机构；MedPath 不保证数据的完整性或准确性。请以原始资料为准。

© 2026 MedPath Trial 版权所有

服务条款隐私政策

我们重视您的隐私

我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。

Pfizer SA

首页临床试验发起方与机构Pfizer SA

Pfizer SA

ACTIVE

Av. Libertador, Caracas, Distrito Federal, 委内瑞拉Subsidiary

隶属于 PFIZER INC.

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

相关临床试验

119

56 进行中

药物批准

8

批准总数

监管机构

2

监管机构数

成立时间

N/A

概览

试验阶段分布

阶段

试验数

占比

不适用

64

53.8%

1 期

37

31.1%

试验状态分布

进行中（未招募）

55

46.2%

已完成

56

47.1%

尚未招募

1

0.8%

招募中

1

0.8%

相关临床试验

该机构主办的试验（119）

A PHASE 3 RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROLLED, MULTICENTER STUDY OF THE LONG- TERM SAFETY AND EFFICACY OF SUBCUTANEOUS ADMINISTRATION OF TANEZUMAB IN SUBJECTS WITH OSTEOARTHRITIS OF THE HIP OR KNEE

Apr 201637 名受试者

A Phase 3 Randomized, Double-Blind Study of PF-06439535 plus Paclitaxel-Carboplatin and Bevacizumab plus Pacitaxel-Carboplatin for the first-line treatment of patients with advanced non-squamous non-small cell lung cancer.

A PHASE 3B/4 RANDOMIZED DOUBLE BLIND STUDY OF 5 MG OFTOFACITINIB WITH AND WITHOUT METHOTREXATE IN COMPARISON TOADALIMUMAB WITH METHOTREXATE IN SUBJECTS WITH MODERATELYTO SEVERELY ACTIVE RHEUMATOID ARTHRITIS

May 201517 名受试者

A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY OF PF-05280586VERSUS RITUXIMAB FOR THE FIRST-LINE TREATMENT OF PATIENTSWITH CD20-POSITIVE, LOW TUMOR BURDEN, FOLLICULAR LYMPHOMA

May 20155 名受试者

A PHASE 3 RANDOMIZED, DOUBLE-BLIND STUDY OF PF-05280014 PLUS PACLITAXEL VERSUS TRASTUZUMAB PLUS PACLITAXEL FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH HER2-POSITIVE METASTATIC BREAST CANCER

Dec 20148 名受试者

PHASE 3B/4 RANDOMIZED SAFETY ENDPOINT STUDY OF 2 DOSES OF TOFACITINIB IN COMPARISON TO A TUMOR NECROSIS FACTOR (TNF) INHIBITOR IN SUBJECTS WITH RHEUMATOID ARTHRITIS

Nov 2014190 名受试者

AN OPEN-LABEL BOSUTINIB TREATMENT EXTENSION STUDY FOR SUBJECTS WITH CHRONIC MYELOID LEUKEMIA (CML) WHO HAVE PREVIOUSLY PARTICIPATED IN BOSUTINIB STUDIES B1871006 OR B1871008

Jul 20142 名受试者

A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTI-CENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ONCE-DAILY ADMINISTRATION OF A CHEMOKINE CCR2/5 RECEPTOR ANTAGONIST (PF-04634817) IN ADULTS WITH TYPE 2 DIABETESAND OVERT NEPHROPATHY

Dec 201310 名受试者

第 1 页，共 15 页

药物批准

按机构分类的批准

NMPA

National Medical Products Administration

2

药物批准

SFDA

Saudi Food and Drug Authority

6

药物批准

近期批准

PROSTIN E2 2MG VAGINAL GEL IN APPLICATOR

PROSTIN E2 VAGINAL TAB. 3MG

GENOTROPIN 16IU CARTRIDGE

PROSTIN E2 1MG VAGINAL GEL IN APPLICATOR

GENOTROPIN GOQUICK 12MG PRE-FILLED PEN

Genotropin GoQuick 5.3 mg

Methylprednisolone Sodium Succinate for Injection

Methylprednisolone Sodium Succinate for Injection

资讯

暂无资讯文章

本页目录

概览
相关临床试验119
药物批准8
资讯

返回机构列表